Roche Says EU Approves Lymphoma Treatment Lunsumio
June 08 2022 - 1:49AM
Dow Jones News
By Cecilia Butini
Roche Holding AG said Wednesday that the European Commission has
granted conditional marketing authorization for its cancer
immunotherapy drug, Lunsumio, which was studied for use in patients
with relapsed or refractory follicular lymphoma.
The Swiss pharma company said the drug is a new type of
treatment which is chemotherapy-free and has a fixed duration. The
treatment is off-the-shelf and readily available, which means that
people don't have to wait to start treatment, the company said.
The European Union's approval is based on data from a Phase 1-2
trial. Conditional approval is granted to a drug that fulfils an
unmet medical need, meaning the benefit of immediate availability
outweighs the risk of having less comprehensive data, Roche
said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
June 08, 2022 01:34 ET (05:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
